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Background: Single-chain urokinase-type plasminogen activator (sc-uPA) is one of the key serine proteases involved in
modulating cellular and extracellular matrix responses during tissue remodeling. Sc-uPA is composed of three domains:
aminoterminal fragment (ATF), kringle domain, and carboxyterminal fragment (CTF). sc-uPA is readily cleaved into
these three domain fragments in vitro, each of which is biologically active; however, their roles in the microenvironment
of the vessel wall are poorly understood.
Purpose: The purpose of this study was to determine the role of each domain of sc-uPA on vascular smooth muscle cell
(SMC) proliferation and migration.
Methods: SMCs were cultured in vitro. Assays of DNA synthesis, cell proliferation, and migration were performed in
response to sc-uPA, ATF, kringle, and CTF in the presence and absence of the plasmin inhibitors -aminocaproic acid
(EACA) and aprotinin, the Gi inhibitor pertussis toxin, and the mitogen-activated protein kinase 1 (the upstream
regulator of the extracellular-signal regulated kinase [ERK]) inhibitor PD98059.
Results: sc-uPA produced dose-dependent increases in DNA synthesis and cell proliferation. These responses were
dependent on the CTF domain and were sensitive to plasmin inhibitors, pertussis toxin, and PD98059. Sc-uPA also
induced SMC migration, which could be elicited by both ATF and kringle. Migration to sc-uPA, ATF, and kringle was
both pertussis toxin and PD98059 sensitive, but importantly was plasmin-independent.
Conclusion: sc-uPA induces SMC proliferation and migration, which are domain-dependent and mediated in part by
Gi-linked, ERK-dependent processes, while only the mitogenic response is protease dependent. These findings suggest
that migration is linked to a G-protein coupled nonprotease receptor, while proliferation is associated with a G-protein
coupled protease receptor. (J Vasc Surg 2004;39:214-22.)
Recurrent stenosis, the anatomic result of intimal hy-
perplasia and remodeling, remains an obstacle to the long-
term patency of conventional and endoluminal vascular
interventions.1 Intimal hyperplasia involves an integrated
program of cell proliferation, migration, and extracellular
matrix modulation. Proliferation and migration of smooth
muscle cells (SMCs) involves the complex regulation of
proteases, integrins, and extracellular molecules within the
microenvironment of the vessel wall. Urokinase plasmino-
gen activator (uPA), a serine protease, is the primary plas-
minogen activator in tissue remodeling,2 and is secreted as
a single chain subunit (sc-uPA) and localized to the mem-
brane by its receptor, the uPA receptor (uPAR).3 Within
this microenvironment uPA protease activity is controlled
by plasminogen activator inhibitor-1 (PAI-1).4 sc-uPA is
cleaved in vitro into three fragments: aminoterminal
(ATF), kringle, and carboxyterminal (CTF). Matrix metal-
loproteinase (MMP)–3 cleaves uPA in vitro into ATF and
CTF fragments with the same functional domains as those
used in our experiments5; the likelihood that similar cleav-
age products occur in vivo is high. Each fragment has
unique characteristics in the microenvironment of the ves-
sel wall.6,7 We tested the hypothesis that sc-uPA induces
SMC proliferation and migration through Gi-linked re-
ceptors and a protease-mediated, extracellular signal-regu-
lated kinase (ERK)–dependent process.
METHODS
Experiment design. Sprague-Dawley rat vascular
SMCs were cultured in vitro. Standard assays of DNA
synthesis (thymidine incorporation), cell proliferation
(manual cell counting), and migration (linear wound assay)
were used in response to sc-uPA, ATF, kringle, and CTF in
the presence and absence of the plasmin inhibitors aproti-
nin and aminocaproic acid (EACA), the Gi inhibitor
pertussis toxin, the Gq inhibitor GP-2A, and the mitogen
activated protein kinase 1 (MEK1) inhibitor PD98059.
Materials. Single-chain uPA, ATF, kringle, and CTF
were purchased from American Diagnostica (Greenwich,
Conn). According to the manufacturer, sc-uPA was puri-
fied from the media of an sc-uPA–secreting kidney cell line,
and purified with affinity column chromatography, result-
ing in 100% zymogen with a specific activity of 90,000
IU/mg urokinase equivalent. CTF was produced by con-
trolled proteolysis of uPA isolated from human urine, and
contains more than 95% low molecular weight uPA (CTF)
and less than 5% high molecular weight uPA (intact uPA).
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The specific activity of the resultant product was 160,000
IU/mg, and PAI-1 binding was confirmed. ATF is a re-
combinant product representing amino acids 1 to 143 of
human uPA, including the growth factor–like and kringle
domains, and specifically binds with high affinity to the uPA
receptor. EACA, aprotinin, and pertussis toxin were pur-
chased from Sigma (St Louis, Mo). PD98059 was pur-
chased from Calbiochem (La Jolla, Calif). GP-2A was
purchased from Biomol (Plymouth Meeting, Pa). Peroxi-
dase-conjugated anti-rabbit immunoglobulin G (IgG) an-
tibody was purchased from Jackson ImmunoResearch Lab-
oratories (West Grove, Pa). Peroxidase-conjugated anti-
mouse IgG antibody was purchased from BioRad
Laboratories (Hercules, Calif). Phospho-ERK antibody
was purchased from Promega (Madison, Wis). Total ERK
antibody was purchased from BD Transduction Laborato-
ries (Lexington, Ky). Delbecco modified Eagle medium
(DMEM) and deionized phosphate-buffered saline solu-
tion were purchased from Cellgro (Herndon, Va).
[H3]-thymidine incorporation. The technique used
for [H3]-thymidine incorporation has been described in
detail.8 In brief, 24-well cluster dishes (Falcon Plastics,
Madison, SD) were inoculated with 5  104 cells per well
and allowed to reach about 70% confluence. The medium
was changed to DMEM for 2 days to induce cell quies-
cence. [H3]-thymidine (1Ci/mL; ICN, Irvine, Calif) was
added with serum (10% fetal bovine serum), sc-uPA (0.1-
100 nmol/L), or domain fragments (0.1-100 nmol/L),
with and without pharmacologic inhibitors. Incorporation
of [H3]-thymidine into acid-precipitable material was mea-
sured after 24 hours of incubation (air plus 5% carbon
dioxide at 37°C). Aliquots were counted in 5 mL of Cyto-
scint (ICN Research Products, Costa Mesa, CA) with a
scintillation counter (Beckman Instruments, Fullerton,
Calif).
Cell proliferation. The technique used to assay cell
proliferation has been described.8 Cell proliferation in re-
sponse to serum (10% fetal calf serum), sc-uPA (10 nmol/
L), or domain fragments (10 nmol/L) with and without
pharmacologic inhibitors was determined (see Results for
time points). Cells from each well were removed with
trypsinization, and were counted with a hemocytometer
(Hausser Scientific, Horsham, Pa).
Wound assay. The technique used for wound assay
has been described.9 In brief, confluent SMCs in 60 mm2
dishes were starved for 24 hours. Each dish was divided into
a 2  3 grid, and a linear wound was made in each
hemisphere of the dish. Photomicrographs were taken of
the intersections of the linear wound and each grid line
(eight fields per dish) at time 0 and at 24 hours. Cells were
allowed to migrate at 37°C in DMEM with or without
sc-uPA (10 nmol/L), ATF (10 nmol/L), kringle (10
nmol/L), or CTF (10 nmol/L). Subsequently, migration
in response to these agonists was examined in the presence
of aprotinin (100 units/mL), EACA (100 mol/L), per-
tussis toxin (100 ng/mL), GP-2A (10 mol/L), or
PD98059 (25 mol/L). Eight fields from each dish were
averaged. Trials with each reagent or inhibitor were per-
formed in at least six separate dishes, and the results were
averaged.
Western blot technique. The technique for in vitro
cell stimulation and Western blotting for phosphorylated
and total ERK1/2 has been described in detail.9 In brief,
SMCs at 80% confluence were starved for 24 hours, stimu-
lated with agonists alone or with inhibitors, and harvested
(see Results for time points). Equal amounts of protein
lysates (25 g) were loaded onto 12.5% polyacrylamide
gels, separated with electrophoresis, and transferred to
nitrocellulose membranes (BioRad). After blocking in 5%
nonfat milk, blots were immunostained with antibodies to
phosphorylated or total ERK. Protein bands were visual-
ized with anti-rabbit (phospho-ERK) or anti-mouse (total
ERK) IgG horseradish peroxidase–conjugated antibodies,
followed by enhanced chemiluminescence (Amersham, Ar-
lington Heights, Ill), according to the manufacturer’s pro-
tocols. Band intensity was measured with Gel-Imaging
software (Kodak, Rochester, NY).
Data and statistical analysis. All data are presented as
mean  SEM. Statistical differences between groups were
tested with the Kruskal-Wallis nonparametric test, with
post hoc Dunn multiple comparison correction where ap-
propriate. P  .05 was regarded as significant; nonsignifi-
cant differences are expressed as P  NS.
RESULTS
sc-uPA induces smooth muscle cell migration. sc-
uPA induced migration of SMCs in a wound assay (Fig 1,
A). This response was reproduced with ATF and kringle,
but not with CTF (Fig 1, A). Incubation with the plasmin
inhibitors EACA and aprotinin did not inhibit migration
stimulated by sc-uPA, ATF, or kringle (Fig 1, B). The
migration response to ATF was significantly decreased with
addition of pertussis toxin, suggesting a receptor-linked,
Gi-mediated response (Fig 1, C). The Gq inhibitory
peptide, GP-2A, had no effect on migration induced with
ATF. Cell migration to ATF was sensitive to am MEK1
inhibitor (PD98059), suggesting that the response is ERK-
dependent. Similar migration results were obtained for
sc-uPA and kringle (Fig 1, D, E online only).
The Western blot technique demonstrated that sc-
uPA, ATF, and kringle induced time-dependent increases
in ERK phosphorylation, with maximum ERK activation at
15 to 20 minutes (Fig 3, A-C). There were no changes in
total ERK at any time for any of the time courses studied
(data not shown). Phosphorylation of ERK by sc-uPA was
sensitive to plasmin inhibitors (Fig 2, D, online only; Fig 3,
A); phosphorylation of ERK by ATF and kringle was not
(Fig 2, E, F, online only; Fig 3, B, C). ERK phosphorylation
induced by Sc-uPA, ATF, and kringle was sensitive to both
Gi and MEK1 inhibition (Fig 2, A; Fig 2, D-F, online
only; Fig 3, A-C).
sc-uPA induces SMC proliferation. Sc-uPA pro-
duced a concentration-dependent increase in DNA synthe-
sis (Fig 4, A, B) and a time-dependent increase in cell
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proliferation (Fig 4, C). These responses were induced by
CTF, but not by ATF or kringle (Fig 4, A, B). Incubation
with EACA and aprotinin at concentrations that markedly
diminish plasmin activity significantly inhibited sc-uPA–
mediated DNA synthesis (Fig 5, A). DNA synthesis stim-
ulated with CTF and sc-uPA was significantly decreased at
preincubation with pertussis toxin, suggesting a receptor-
linked, Gi-mediated response (Fig 5, B; C, online only).
Incubation with GP-2A had no effect. Both sc-uPA and
CTF induced thymidine incorporation that was sensitive to
an MEK1 inhibitor (PD98059), suggesting that these re-
sponses were ERK-dependent (Fig 5, B; C, online only).
Both sc-uPA and CTF produced time-dependent increases
in ERK phosphorylation that were sensitive to inhibitors of
plasmin, Gi, and MEK1 (Fig 2, A-C; D, online only; Fig
3, A, D).
DISCUSSION
Studies suggest that plasminogen activators and plas-
min have a significant role in development of intimal hy-
perplasia. After injury to the rat carotid artery, there are
increases in expression of uPA and tissue-type plasminogen
activator (tPA) and in plasminogen activator activity on
SMCs within the vessel wall.10 Tranexamic acid, a plasmin
inhibitor, reduces SMC migration after carotid balloon
injury.11 When uPA is placed in a pluronic gel around an
injured carotid artery, there is a significant increase in
development of intimal hyperplasia.12 Expression of PAI-1,
an endogenous plasminogen activator inhibitor, is in-
creased sevenfold 3 hours after injury, and returns to base-
line by 2 days; it then increases again from days 4 to 7.13,14
Elevated PAI-1 in the rat carotid artery enhances thrombo-
sis and endothelial cell regeneration and inhibits intimal
thickening.15 Overexpression of uPA and deficiency of
PAI-1 in transgenic mice promote neointimal formation in
response to electrical injury.16-18 However, in mice with-
out uPAR, neointima formation is unchanged.4 Plasmin is
clearly important, and it appears that in arterial injury
plasmin generation by uPA, but not tissue-type plasmino-
gen activator, is involved in stimulation of cell migration
and neointima formation.19 Plasminogen knockout mice
do not develop intimal hyperplasia compared with control
mice, and show no MMP-9 activation (although MMP-2
activation is unchanged).20 Lamfers et al,21 using a vector
composed of ATF and bovine pancreas trypsin inhibitor,
showed a reduction in neointima formation, presumably by
inhibiting SMC migration. The present in vitro data dem-
onstrate roles for sc-uPA and, more important, its individ-
ual domains in both proliferation and migration of SMCs.
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Fig 1. (Continued) control for six experiments. C, Migration
response to ATF in the wound assay with and without pertussis
toxin (PTx; 100 ng/mL), GP-2A (a Gq inhibitory peptide; 10
mol/L), or a mitogen-activated protein kinase–1 inhibitor
(PD98059, PD; 25 mol/L). Values represent mean  SEM of
percent of control for six experiments (**P  .01, ATF alone).
Fig 1. A, Migration in response to single-chain urokinase-type
plasminogen activator (sc-uPA; 10 n mol/L), amino-terminal frag-
ment of uPA (ATF; 10 nmol/L), kringle (10 n mol/L), and
carboxy-terminal fragment of uPA (CTF; 10 nmol/L) in the
wound assay. Confluent plates were scratched, and reagents were
added at time 0; cells were then allowed to migrate over 24 hours.
Larger decreases in wound area (more negative values) represent
increased migration. Values represent mean  SEM percent of
control for six experiments (**P .01 vs control). B, Migration in
response to sc-uPA (10 n mol/L), ATF (10 n mol/L), and kringle
(10 n mol/L) in the wound assay, with and without the plasmin
inhibitors -aminocaproic acid (EACA, 100 mol/L) and aproti-
nin (100 units/mL). Values represent mean  SEM of percent of
JOURNAL OF VASCULAR SURGERY
January 2004216 Tanski et al
sc-uPA is a chemotactic factor in many cell lines, and
apparently requires ATF, which has a uPAR binding do-
main. We have shown here that sc-uPA stimulates migra-
tion through both ATF and kringle fragments of the
molecule, and does not require protease activity. We have
also observed that ATF stimulates SMC migration when
Fig 2. A, Densitometric measurements of time-dependent extracellular signal-regulated kinase (ERK)–1/2 phos-
phorylation in response to carboxy-terminal fragment (CTF; 10 nmol/L) in the presence and absence of plasmin
inhibitors aprotinin (100 units/mL) and -aminocaproic acid (EACA; 100 mol/L). ERK phosphorylation is expressed as
increase over time 0 control. B, C, Maximal ERK phosphorylation for single-chain urokinase-type plasminogen activator
(sc-uPA; 10 nmol/L [B, C]), amino-terminal fragment of uPA (ATF; 10 nmol/L [B]), kringle (10 nM, [B]), and
carboxy-terminal fragment of uPA (CTF; 10 nmol/L [C]) in the presence and absence of Gi inhibitor pertussis toxin (PTx;
100 ng/mL) and mitogen-activated protein kinase–1 inhibitor PD98059 (PD; 25 mol/L). All values represent mean
SEM of percent of control for three experiments (*P .05, **P .01, vs agonist alone).
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placed in the bottom well of a modified Boyden chamber
with a Matrigel-coated membrane, supporting its role as a
chemoattractant in an invasion model (unpublished obser-
vations). Others have shown that cell migration depends on
specific mutant sc-uPA molecules containing either ATF or
kringle.22,23 The respective importance of each of these
domains in migration is not resolved. The response to ATF
may be due to binding and cleavage of a glycosyl phosphati-
dyl inosital (GPI)	linked uPA receptor (uPAR). This re-
ceptor is composed of three domains (D1D2D3); on bind-
Fig 3. A-D, Representative Western blots of extracellular signal-regulated kinase (ERK)–1/2 phosphorylation in
response to single-chain urokinase-type plasminogen activator (sc-uPA; 10 n mol/L [A]), amino-terminal fragment
(ATF; 10 n mol/L [B]), kringle (10 n mol/L [C]), and carboxy-terminal fragment (CTF; 10 n mol/L [D]) in the
presence and absence of the plasmin inhibitors aprotinin (100 units/mL) and -aminocaproic acid (EACA; 100
mol/L), Gi inhibitor pertussis toxin (PTx; 100 ng/mL), and mitogen-activated protein kinase–1 inhibitor
PD98059 (25 mol/L). P44, Phosphorylated form of ERK2; p42, phosphorylated form of ERK1. Cells were
pretreated with inhibitors for 30 minutes. Blots are representative of three experiments for each time course. Bands
labeled with agonists (eg, uPA) or inhibitors (eg, pertussis toxin) represent positive and negative controls, respectively.
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ing with ATF it is cleaved into a cell-bound D1 fragment
containing the GPI tail and a soluble D2D3 fragment.
D2D3 then binds to the low-affinity receptor of chemotac-
tic peptide fMPL, FRAL-1, to induce a Gi-mediated
migration response. The ATF response is Gi-linked, but
not Gq-linked, and is ERK-dependent; similar results
were observed in a modified Boyden chamber with a Ma-
trigel-coated membrane (unpublished observations). We
cannot exclude the possibility that these effects are G
-
mediated. Little is known about the mechanism whereby
kringle induces migration. We have demonstrated that it is
partially Gi-linked, but not Gq-linked, and is ERK de-
pendent. Kringle may induce ERK activation through re-
ceptor-dependent and receptor-independent mechanisms,
which may explain why pertussis toxin did not eliminate the
migration response entirely. Commercially made ATF con-
tains the kringle fragment, and thus may also act through
both receptor-dependent and receptor-independent mech-
Fig 3. (Continued.)
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Fig 4. A and B, In vitro [3H]- thymidine incorporation into DNA of cultured rat vascular smooth muscle cells in
response to 0.1 to 100 n mol/L of single-chain urokinase-type plasminogen activator (sc-uPA), carboxy-terminal
fragment of uPA (CTF), amino-terminal fragment of uPA (ATF), and kringle. B represents results for each agonist at
10 n mol/L. Values represent mean SEM of increase over control for four experiments (**P .01 vs control). C,
Cell proliferation in response to sc-uPA (10 n mol/L) and CTF (10 n mol/L) as measured by cell counting. ATF and
kringle at 10 n mol/L did not stimulate cell proliferation (data not shown). Reagents were added at time 0. Serum
(10%) and DMEM represent positive and negative controls, respectively. Values represent mean SEM of increase over
control for six experiments.
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anisms. The ability of ATF and kringle to induce migration
may explain why, in vivo, mice without uPAR do not
exhibit reduced neointima formation.4 In vitro data sug-
gest that plasmin and MMPs cleave uPA into its respective
fragments, and CTF and kringle fragments may compen-
sate for inability of ATF to cleave and activate absent uPAR.
Transgenic murine models suggest that uPA has a
significant role in stimulating proliferation and that it is
plasmin-dependent. Using mutants of sc-uPA, others have
shown that cell proliferation requires the CTF portion.22,23
CTF contains a protease domain, and leads to plasmin
generation, whereas plasmin inhibition reduces DNA syn-
thesis. Plasmin induces ERK-dependent SMC proliferation
(unpublished observations). CTF may mediate SMC pro-
liferation by three separate mechanisms. First, plasmin may
activate MMPs, leading to epidermal growth factor recep-
tor–dependent mitogen-activated protein kinase activa-
tion.20,24 Inhibition of plasminogen activation decreases
plasmin and thus MMP activation. Activation of epidermal
growth factor receptor by sc-uPA and CTF may explain our
incomplete inhibition of DNA synthesis in the presence of
pertussis toxin. Second, plasmin interacts with the pro-
tease-activated receptor PAR-1 (a thrombin receptor), pos-
sibly using annexin as a cofactor, in a manner distinct from
the protease thrombin.25 The PAR-1 receptor is G protein–
coupled, and may bind to either Gi or Gq; our data
suggest that it is Gi-dependent and may involve G
.
Third, preliminary data from other authors suggest that
CTF may bind to a novel cell surface receptor independent
of uPAR and PAR-1, which remains to be identified. Inas-
much as no plasmin was added during CTF stimulation in
our experiments, it is possible that this third mechanism is
indeed significant and that plasmin inhibitors affect other
necessary intermediates downstream of G protein–coupled
receptors. Alternatively, some plasminogen may remain in
cell culture despite removal of serum during “starving.”
sc-uPA is a pluripotent molecule with the ability to
induce both cell migration and proliferation through G
protein–coupled receptors. Migration is protease-indepen-
dent, whereas cell proliferation is protease-dependent and
may be mediated through G protein–coupled, protease-
dependent receptors.
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